4: Statement of changes in beneficial ownership of securities

• Post author:andrewkaretas
• Post published:December 10, 2024
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading4: Statement of changes in beneficial ownership of securities

4: Statement of changes in beneficial ownership of securities

• Post author:andrewkaretas
• Post published:December 9, 2024
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading4: Statement of changes in beneficial ownership of securities

144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

• Post author:andrewkaretas
• Post published:December 9, 2024
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

144/A: Amendment to a previously filed 144

• Post author:andrewkaretas
• Post published:December 4, 2024
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading144/A: Amendment to a previously filed 144

144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

• Post author:andrewkaretas
• Post published:December 2, 2024
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

8-K: Report of unscheduled material events or corporate event

• Post author:andrewkaretas
• Post published:November 13, 2024
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading8-K: Report of unscheduled material events or corporate event

SC 13G/A: An amendment to the SC 13G filing

• Post author:andrewkaretas
• Post published:November 12, 2024
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingSC 13G/A: An amendment to the SC 13G filing

SC 13G/A: An amendment to the SC 13G filing

• Post author:andrewkaretas
• Post published:November 8, 2024
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingSC 13G/A: An amendment to the SC 13G filing

10-Q: Quarterly report which provides a continuing view of a company’s financial position

• Post author:andrewkaretas
• Post published:November 7, 2024
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading10-Q: Quarterly report which provides a continuing view of a company’s financial position

8-K: Report of unscheduled material events or corporate event

• Post author:andrewkaretas
• Post published:November 7, 2024
• Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading8-K: Report of unscheduled material events or corporate event